AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$MEDP

Carley Brian T sold $3.0M of MEDP

Carley Brian T sold 5,000 shares of Medpace Holdings, Inc. (MEDP) at $608.63 ($3.04M total) on 2026-08-19.

Original reporting
SEC EDGAR · Carley Brian T
Published Aug 21, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The disclosed sale provides fresh data for traders assessing insider sentiment.

02

Market read

Insider sales can influence short-term price movement; traders may watch MEDP for volatility.

03

What to watch

No accompanying corporate news; the director may be diversifying assets.

Relevance 6/10Novelty 6/10Timing: filed today

Background

Form 4 filings disclose insider transactions; a director's sale is publicly reported.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

Director Carley Brian T sold 5,000 shares for $3.04M, reducing his stake to 27,825 shares.

Expected impact

Possible modest downside of 2-4% over the next few days.

Evidence & confidence

A $3M insider sale by a director is material but not unusually large; market may react cautiously.

Market effects

Sector

Minimal impact on the broader healthcare services sector.

Regional

Limited to U.S. markets where MEDP trades.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Medpace Holdings, Inc.

    Clinical research organization listed on NASDAQ.

  • Insider
    Carley Brian T

    Director of Medpace who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MEDP insider trading history →

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min